A study comparing the cost-effectiveness of endoscopic sleeve gastroplasty (ESG) and semaglutide over a 5-year period in patients with class II obesity found that ESG resulted in greater weight loss and was more cost-effective than semaglutide. ESG led to better weight loss outcomes and added more quality-adjusted life years (QALYs) compared to semaglutide. Semaglutide was more expensive than ESG over the 5-year period, with an incremental cost-effectiveness ratio (ICER) favoring ESG. The study suggests that choosing cost-saving yet effective treatments like ESG for specific patient groups could help mitigate budget strains associated with more expensive treatments like semaglutide.
Source link
ESG More Cost-Effective Long Term Than Semaglutide
